泽璟制药：注射用ZG006纳入突破性治疗品种公示名单

Core Viewpoint - The company Zai Lab announced that its investigational product ZG006 has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) of China, indicating significant potential for the treatment of advanced small cell lung cancer patients who have previously undergone platinum-based chemotherapy and at least one other systemic therapy [1] Group 1 - ZG006 is indicated for the treatment of patients with advanced small cell lung cancer who have experienced recurrence or progression after third-line or higher treatment [1] - The public notice period for ZG006 is from July 9, 2025, to July 16, 2025 [1] - ZG006 is a trispecific T-cell engager targeting two different DLL3 epitopes and CD3, suggesting its potential to become a best-in-class molecule in its category [1]